Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,692 across all filing types
Latest filing 2026-05-18 Board/Management Inform…
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
公告本公司法人董事改派代表人暨三分之一以上董事 發生變動
Board/Management Information Classification · 93% confidence The document is an official announcement by a listed company on the public information observation station (MOPS) detailing changes in its board composition—specifically the replacement of a corporate director’s representative and noting that more than one-third of directors have changed. This fits the definition of a board/management information announcement.
2026-05-18 Chinese
115年年報及股東會資料 — 2026_1783_20260611FE2.pdf
AGM Information Classification · 89% confidence The document is titled the “2026 Annual Shareholders’ Meeting Meeting Handbook” for Maxigen Biotech Inc. and contains the full agenda, procedures, reporting items, approval proposals, and attachments (business report, audit committee review, auditor’s report and financials, compensation report, articles, etc.) for the Annual General Meeting. It is clearly the set of materials prepared for and shared at the company’s AGM rather than the standalone annual report or proxy statement. This falls squarely under “AGM Information” (materials shared during the AGM).
2026-05-11 English
115年年報及股東會資料 — 2026_1783_20260611F02.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is the “議事手冊” (meeting handbook) for the 2026 Annual General Meeting of Maxigen Biotech Inc. It contains the AGM agenda, proposals for approval (2025 annual business report, financial statements, profit distribution, director remuneration, etc.), and attachments (annual report, audit committee report, auditor’s report, financial statements, corporate charter and rules, director shareholdings). This is not the annual report itself but the information/proxy materials provided to shareholders to solicit votes at the AGM. Hence it fits “Proxy Solicitation & Information Statement” (PSI).
2026-05-11 Chinese
115年年報及股東會資料 — 2026_1783_20260611F13.pdf
AGM Information Classification · 86% confidence The document is titled “2026 年股東常會各項議案參考資料” and contains the board‐proposed agenda items, financial report approvals, and profit distribution proposals for the 2026 Annual General Shareholders Meeting. It is a package of materials to be presented and reviewed at the AGM rather than the full annual report or standalone financial statements. This matches the definition of AGM Information (materials shared during the AGM).
2026-05-11 Chinese
115年年報及股東會資料 — 2026_1783_20260611FE1.pdf
Regulatory Filings Classification · 75% confidence The document is a formal notice convening the 2026 Annual Shareholders’ Meeting, including time, location, and agenda items. It does not contain actual financial statements, management discussion, voting results, or proxy solicitation language. It serves as a regulatory announcement of the meeting rather than a financial report or detailed proxy statement. The best fit under the defined categories is Regulatory Filings (RNS) for miscellaneous compliance announcements.
2026-05-11 English
115年年報及股東會資料 — 2026_1783_20260611F01.pdf
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a shareholder meeting notice with proxy solicitation forms, agenda items for the 115th Annual General Meeting, voting instructions, and requisite proxy paperwork. It is sent to shareholders to request votes and provide information ahead of the meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.